Denmark’s Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday. The deal marks a significant expansion of Genmab’s oncology portfolio, adding a promising late-stage cancer therapy candidate to its pipeline.Under the terms of the…
European shares edged higher on Monday, lifted by gains in healthcare and technology, as investors weighed the risk of…
GSK announced on Monday that Chief Executive Emma Walmsley will step down after nine years in the role, with…
The TikTok deal has intrigued the markets experts, not just because of its $14 billion price tag but because…
Following a social media post by US President Donald Trump over the weekend, which suggested potential health benefits from…
BP, a British energy major, announced on Monday its decision to proceed with a $5 billion offshore drilling project…
OpenAI has unveiled robust new parental controls for its flagship chatbot, ChatGPT, marking a pivotal move toward protecting teenagers…
Wells Fargo shares edged lower in premarket trading Monday after Morgan Stanley analyst Betsy Graseck downgraded the bank to…
This week’s top LATAM cryptocurrency news focuses on two key actions in the region: Banco Safra introduced Safra Dollar,…
